SULIPRO

About This Project

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver causing inflammation and eventually lead to permanent scarring (cirrhosis) which can seriously impair the liver’s ability to functions. NAFLD can progress to non-alcoholic steatohepatitis (NASH), and then to liver failure, resulting in death without a liver transplant.

 

As rates of obesity and diabetes rise, so do the levels of NAFLD, now affecting an estimated 26 to 33% of the general population in Europe.

 

There is no therapeutic treatment currently available for patients with NAFLD and NASH. Current drugs produced for liver diseases are extremely expensive, with harsh side effects. Considering the long term usage requirements – around 30-40 years – these drugs are not attractive to patients who are at early or mid stages of disease. Natural “herbal” remedies  are marketed as a treatment for this disease, but have undergone no comprehensive clinical trials and there is no evidence they actually work, therefore they are not promoted as a potential treatment by physicians or pharmacists and treated suspiciously by consumers. Dietary changes combined with regular aerobic exercise has been shown to have an effect, but has been met with low compliance rates.

 

Natural Shield have developed SULIPRO, a scientifically proven, safe, naturally derived oral therapeutic for the effective treatment of the early stages of NAFLD and NASH. A combination of soy derived compounds, SULIPRO has already undergone positive clinical trials in animal models and successful Phase I clinical trials in humans demonstrates high efficacy with no side effects. SULIPRO represents a long-term solution, available over the counter at a much lower cost of approximately €360 per year.

Topic
PHC-12 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Year

2016

Cutoff

November

Beneficiaries

Coordinator

Natural Shield Israel 2016 Limited

Country

Israel